Financial Performance - The company's revenue for the first quarter of 2021 reached RMB 148,719,000, representing a 14.4% increase compared to RMB 129,952,000 in the same period of 2020[4] - Gross profit for the first quarter of 2021 was RMB 125,364,000, up from RMB 111,380,000 in the first quarter of 2020, indicating a growth of 12.6%[4] - Operating profit increased to RMB 23,725,000 in Q1 2021, compared to RMB 16,964,000 in Q1 2020, reflecting a growth of 39.5%[4] - Profit attributable to shareholders for the first quarter of 2021 was RMB 20,108,000, a significant increase of 45.3% from RMB 13,870,000 in the same quarter of 2020[4] - Basic earnings per share for Q1 2021 were RMB 3.59 cents, compared to RMB 2.47 cents in Q1 2020, marking a 45.2% increase[4] - The profit attributable to shareholders for the same period was RMB 20,108,000, representing a 45% increase from RMB 13,870,000 in the previous year[16] - The basic earnings per share for the three months ended March 31, 2021, was RMB 3.59 cents[16] Revenue Sources - All revenue generated in the first quarter of 2021 was from domestic sales within China, with no identifiable assets located outside the country[8] - For the three months ended March 31, 2021, the group recorded revenue of approximately RMB 148,719,000, an increase of approximately RMB 18,767,000 compared to the same period last year[16] Cost and Margin Analysis - The gross margin for the same period was approximately 84.3%, a decrease of 1.4% from 85.7% in the previous year[16] - Distribution and selling costs as a percentage of revenue decreased to 46.2% from 78% in the previous year, a reduction of 31.8%[16] Cash and Assets - As of March 31, 2021, the group's cash and bank balances totaled RMB 818,180,000, compared to RMB 131,450,000 in the previous year[19] - The group's net asset value as of March 31, 2021, was approximately RMB 1,365,590,000, an increase from RMB 1,252,403,000 in the previous year[19] - The capital debt ratio as of March 31, 2021, was 0.03%, down from 0.2% in the previous year[20] Business Operations - The company has not reported any changes in its main business operations, which focus on the manufacturing and distribution of traditional Chinese medicine and pharmaceutical products in China[5] - The company upgraded production facilities and purchased new equipment to enhance production capacity and meet market demand[18] - The company plans to develop and produce 16 new varieties of generic drugs in newly constructed production workshops[18] Dividends and Shareholder Information - The board of directors proposed a special dividend of RMB 3.5 cents per share for the previous fiscal year, totaling RMB 19,608,750, which is the same as the previous year[12] - The company did not purchase, sell, or redeem any of its listed shares during the three months ended March 31, 2021[45] Governance - The audit committee is composed solely of independent non-executive directors, ensuring accountability and independent decision-making[43] - The company’s chairman and CEO, Zhang Hong, is also the major shareholder, contributing to the group's growth and profitability[42]
吉林长龙药业(08049) - 2021 Q1 - 季度财报